The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | AML: ivosidenib is coming
Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the use of ivosidenib in the treatment of acute myeloid leukemia (AML) and myelodysplasia for patients with a specific genetic abnormality either alone or as part of combination therapy. Speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Vyas also comments that ivosidenib is available in the USA, is being considered by the European Medicines Agency (EMA) and is available in the UK via clinical trials.
